Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    StockNews24StockNews24
    Subscribe
    • Shares
    • News
      • Featured Company
      • News Overview
        • Company news
        • Expert Columns
        • Germany
        • USA
        • Price movements
        • Default values
        • Small caps
        • Business
      • News Search
        • Stock News
        • CFD News
        • Foreign exchange news
        • ETF News
        • Money, Career & Lifestyle News
      • Index News
        • DAX News
        • MDAX News
        • TecDAX News
        • Dow Jones News
        • Eurostoxx News
        • NASDAQ News
        • ATX News
        • S&P 500 News
      • Other Topics
        • Private Finance News
        • Commodity News
        • Certificate News
        • Interest rate news
        • SMI News
        • Nikkei 225 News1
    • Carbon Markets
    • Raw materials
    • Funds
    • Bonds
    • Currency
    • Crypto
    • English
      • العربية
      • 简体中文
      • Nederlands
      • English
      • Français
      • Deutsch
      • Italiano
      • Português
      • Русский
      • Español
    StockNews24StockNews24
    Home » Biogen proposes to buy remaining stake in Sage in $442 million deal
    Cryptocurrency News

    Biogen proposes to buy remaining stake in Sage in $442 million deal

    userBy userJanuary 12, 2025No Comments1 Min Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    (Reuters) – Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter’s stock up 34% in extended trade.

    As per the filing, Biogen has a 10.2% stake in Sage Therapeutics. The offer price, representing a 30% premium to the stock’s close on Friday, values Sage’s equity at $441.7 million, according to Reuters calculations.

    Biogen has been navigating a slow pick-up in sales for its Alzheimer’s drug Leqembi in the United States after concerns over cost, efficacy and side effects.

    Sage, whose shares fell 74.9% last year, abandoned the development of its drug dalzanemdor after multiple trial failures. The company said in November that it will focus on its postpartum depression drug, Zurzuvae, which it developed in partnership with Biogen.

    In July, Sage also scrapped the development of another neurological disorder drug it was developing with Biogen.

    (Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona)



    Source link

    Share this:

    • Click to share on Facebook (Opens in new window) Facebook
    • Click to share on X (Opens in new window) X

    Like this:

    Like Loading...

    Related

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleHow much would a SIPP investor need to invest to earn a £1,000 monthly passive income?
    Next Article Investing £5k in each of these 3 FTSE stocks in January 2023 would have created a £55k ISA!
    user
    • Website

    Related Posts

    What Does It Mean to Be Risk Neutral as an Investor?

    January 18, 2025

    SLB boosts dividend and buybacks, but warns of oil oversupply

    January 17, 2025

    Intel Stock Soars as Takeover Speculation Spreads

    January 17, 2025
    Add A Comment

    Leave a ReplyCancel reply

    © 2025 StockNews24. Designed by Sujon.

    Type above and press Enter to search. Press Esc to cancel.

    %d